DAFTAR PUSTAKA
1. Schorge JO et al, Epithelial ovarian cancer in Williams Gynecology, 1st ed. New York, Mc Graw Hill, 2008,p 716-20
2. Nodin B. Immunohistochemical And Molecular Studies On Ovarian Cancer Progression And Prognosis. Doctoral Dissertation. Denmark : Lund University, Clinical Sciences; 2013. Report No.: Isbn 978-91-87449-49-9/ Issn 1652-8220.
3. Suhonen K. Prognostic Role of Cell Adhesion Factors and Angiogenesis in Epithelial Ovarian Cancer. Doctoral Dissertation. Kuopio: University of Kuopio. Clinical Medicine 2007. Report No: ISBN 978-951-27-0752-2/ ISSN 1235-0303
4. Aziz MF, Andrijono, Saifuddinn AB. Buku acuan Nasional Onkologi Ginekologi. Yayasan Bina Pustaka Sarwono Prawirohardjo. Departemen Ginekologi dan ginekologi fakultas kedokteran Indonesia. Edisi pertama. 2006; 469 – 527
5. Bugada D, Allegri M, Lavand‟home P, De Kock M, Fanelli G, Review article:
inflammation-based scores: a new method for patient targeted strategies and improved perioperative out come in cancer patients, Hindawi publishing corporation. Biomed research international, vol 2014, article ID 142425
6. C. A.Dinarello, “Theparadox of pro-inflammatory cytokines in cancer,” Cancer
and Metastasis Reviews, vol. 25, no. 3, pp. 307–313, 2006.
8. Argiles JM, Busquets S, Lopez-Soriano FJ. Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care 2003;6:401–6.
9. Lee.S, Choe J, Kim H, Sung J, high sensitivity c-reactive protein and cancer, J epidemiol 2011, 21(3), 161-168
10. S. Lee, S. Y. Oh, S. H. Kim et al., “Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer
patients treated with FOLFOX chemotherapy,” BMC Cancer, vol. 13, article
350, 2013.
11. H.-Y. Hung, J.-S. Chen, C. Y. Yeh et al., “Effect of preoperative neutrophil -lymphocyte ratio on the surgical outcomes of stage II colon cancer patients
who do not receive adjuvant chemotherapy,” International Journal of
Colorectal Disease, vol. 26, no. 8, pp. 1059–1065, 2011.
12. Y.Kishi, S.Kopetz, Y. S. Chun,M.Palavecino, E. K. Abdalla, and J.-N. Vauthey,
“Blood neutrophil-to-lymphocyte ratio predicts survival in patients with
colorectal livermetastases treated with systemic chemotherapy,” Annals of
Surgical Oncology, vol. 16, no. 3, pp. 614–622, 2009.
13. A. M. di Giacomo, L. Calabr`o, R. Danielli et al., “Longterm survival and
immunological parameters in metastatic melanoma patients who responded to
ipilimumab 10 mg/kg within an expanded access programme,” Cancer
Immunology, Immunotherapy, vol. 62, no. 6, pp. 1021–1028, 2013.
15. W.He, C. Yin, G.Guo et al., “Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in
metastatic colorectal cancer,” Medical Oncology, vol. 30, no. 1, article 439,
2013.
16. J. F. Feng, Y. Huang, Q. Zhao, and Q. X. Chen, “Clinical significance of preoperative neutrophil lymphocyte ratio versus platelet lymphocyte ratio in
patients with small cell carcinoma of the esophagus,” The ScientificWorld
Journal, vol. 2013,Article ID 504365, 7 pages, 2013.
17. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T, Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer, in J Gynecol Oncol Vol. 23, No. 4:265-273
18. N. MacDonald, “Terminology in cancer cachexia: importance and status,”
Current Opinion in Clinical Nutrition andMetabolic Care, vol. 15, no. 3, pp.
220–225, 2012.
19. M. J. Proctor,D. S.Morrison,D. Talwar et al., “An inflammationbased
prognostic score (mGPS) predicts cancer survival independent of tumour site:
a Glasgow Inflammation Outcome Study,” British Journal of Cancer, vol. 104,
no. 4, pp. 726–734, 2011.
20. Berek JS. Natarajan Sathima. Ovarian and Fallopian Tube Cancer. Berek &
Novak‟s Gynecology. Lippincott William and Wilkins. 14th edition.2007; 1457
– 1503
22. Tone AA, Salvador S, Finlayson SJ et al, The Role of the Fallopian Tube in Ovarian Cancer, Clinical Advances in Hematology & Oncology Volume 10, Issue 5 May 2012, pp 296-306
23. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26-35.
24. Jordan SJ, Green AC, Whiteman DC, et al. Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis. Int J Cancer. 2008;122:1598-1603.
25. Macciò A and Madeddu C, Inflammation and Ovarian Cancer, Ovarian Cancer
– Basic Science Perspective. 2012 Report No: ISBN: 978-953-307-812-0
26. Wang C, Sun C, C-Reactive Protein and Malignancy: Clinico-Pathological Association and Therapeutic Implication. Reveiw Article, Chang Gung Med J 2009;32:471-82
27. A. T. Toriola, K. Grankvist, C. B. Agborsangaya, A. Lukanova, M. Lehtinen & H.-M. Surcel, Changes In Pre-Diagnostic Serum C-Reactive Protein Concentrations And Ovarian Cancer Risk: A Longitudinal Study, in Annals of Oncology 22: 1916–1921, 2011.
28. Shan W, Liu J. Inflammation; a hidden path to breaking the spell of ovarian cancer. Cell Cycle 2009; 8(19): 3107–3111.
29. Partheen K, New Prognostic Markers In Stage III Serous Ovarian Adenocarcinomas, in thesis, Department of Oncology Institute of Clinical Sciences The Sahlgrenska Academy at University of Gothenburg, 2008. 30. Elshabrani S, Farid A et.al, Evaluation of C-Reactive Protein as a Probable
31. Hefler L A, Concin N et al, Serum C-Reactive Protein as Independent Prognostic Variable in Patiens With Ovarian Cancer, Clin Cancer Res 2008;14(3)
32. Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 1999;85:2526–31.
33. Mc Keown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC. The relationship between circulating concentrations of Creactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer 2004;91:1993–5. Lerebours E, Michel P: Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol 2007, 102:2557-2563.
38. Gupta D, Lammersfeld CA, Vashi PG, Lis CG. A longitudinal analysis investigating the impact of improvement in serum albumin scores on survival in ovarian cancer. Clinical Ovarian cancer. 2009;2(2):106-111.
39. Donohoe CL, Ryan AM, , cancer cachexia : mechanisms and clinical implications, review article, hindawi publishing corp. Vol 2011.
40. Lu H, Ouyang W et al. Inflammation, a key event in cancer development ,Subject Review, mol.cancer res 2006 4(6), april 2006
41. Drenberg DC. Saunders OB. Wilbanks DG et al. Urinary Angiostatin levels are elevated in patients with Epithelial ovarian Cancer. Gynecologic Oncology. USA. 117:2010.117-124
42. M. J. Proctor, P. G. Horgan, D. Talwar, C. D. Fletcher, D. S. Morrison, and D.
C. McMillan, “Optimization of the systemic inflammation-based Glasgow
prognostic score: a Glasgow InflammationOutcome Study,” Cancer, vol. 119,
no. 12, pp. 2325– 2332, 2013.
43. D. C. McMillan, “The systemic inflammation-based Glasgow prognostic score:
a decade of experience in patients with cancer,” Cancer Treatment Reviews,
vol. 39, no. 5, pp. 534–540,2013.
44. Suh KS, Sang WP, Angelica C1, et al. Ovarian cancer biomarkers for molecular biosensors and translational medicine Expert Rev. Mol. Diagn. 10(8), 1069–1083. 2010.
45. Former Anglia Cancer Network. Cancer Research UK. Http://ecric.org.uk/ 46. Rauh-Hain AJ, Del Carmen MG, Recurrent Epithelial Ovarian Cancer: An
48. Madiyono B, Mz Sm, Sastoasmoro S, Budiman I, Purwanto S H. Perkiraan Besar Sampel. Dalam Sastroasmoro S, Ismael S. Dasar Dasar Metodologi Penelitian Klinis. Jakarta: Sagung Seto; 2010. p. 323.
49. Hs-CRP Kit, Pramita Laboratorium Leaflet. 2012
50. Pemeriksaan CRP, Prosedur Tetap Pelayanan Laboratorium, RSUP H.Adam Malik, Medan, Juli 2012
51. Bmi asia WHO expert consultation in Appropriate body-mass index for Asian populations and its implications for policy and intervention Strategies. Public
